Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 8/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.31 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566830 | 0.89 | SMN1; SMN2 (0.38) | NPC1RAB9ABRAFSMN1; SMN2BRD4 | |
| SCHEMBL23748507 | 0.83 | NPC1 (0.55) | NPC1RAB9ABRAFSMN1; SMN2BRD4 | |
| SCHEMBL17372559 | 0.83 | NPC1 (0.55) | NPC1RAB9ABRAFSMN1; SMN2BRD4 | |
| SCHEMBL29638101 | 0.83 | NPC1 (0.55) | NPC1RAB9ABRAFSMN1; SMN2BRD4 | |
| SCHEMBL546925 | 0.82 | — | — | |
| SCHEMBL17372418 | 0.79 | CYP1A2 (0.46) | NPC1RAB9ABRAFSMN1; SMN2BRD4 | |
| SCHEMBL29638102 | 0.79 | CYP1A2 (0.46) | NPC1RAB9ABRAFSMN1; SMN2BRD4 | |
| SCHEMBL545883 | 0.78 | NPC1 (0.38) | NPC1RAB9ABRAFSMN1; SMN2BRD4 | |
| SCHEMBL546176 | 0.77 | CHEK1 (0.32) | HSD17B10 | |
| SCHEMBL17372562 | 0.73 | NPC1 (0.35) | NPC1RAB9ABRAFSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| EP-1625138-A2 | PROTECTED MONOMERS | Alnylam Pharmaceuticals Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | claimed |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11530408-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210254065-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | ALNYLAM PHARMACEUTICALS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-11015194-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2020-08-13 | — | — | US | disclosed |
| US-10676740-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20050153337-A1 | iRNA conjugates | ALNYLAM PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-20050119214-A1 | Nuclease resistant double-stranded ribonucleic acid | ALNYLAM PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | ALNYLAM PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005004794-A2 | METHOD OF TREATING NEURODEGENERATIVE DISEASE | ALNYLAM PHARMACEUTICALS INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004094595-A2 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004091515-A2 | iRNA CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004090108-A2 | IRNA CONJUGATES | ALNYLAM PHARMACEUTICALS (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004080406-A2 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153337-A1 | iRNA conjugates | AGO2, NSUN3, RNASE1 | NPC1 730/4885RAB9A 234/4885BRAF 3928/4885 |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | NPC1 65/4885RAB9A 379/4885BRAF 3603/4885 |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | NPC1 191/4885RAB9A 323/4885BRAF 2871/4885 |
| US-20050119214-A1 | Nuclease resistant double-stranded ribonucleic acid | RNASE1, RNASEH1, RNASEL | NPC1 2213/4885RAB9A 1236/4885BRAF 2876/4885 |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | NPC1 193/4885RAB9A 2350/4885BRAF 3198/4885 |
| US-10676740-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | NPC1 65/4885RAB9A 379/4885BRAF 3603/4885 |
| US-11530408-B2 | Therapeutic compositions | SNRPE, HNRNPH3, RNASE1 | NPC1 193/4885RAB9A 2350/4885BRAF 3198/4885 |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | LDLR, SLC29A1, SLC29A2 | NPC1 10/4885RAB9A 311/4885BRAF 2338/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | NPC1 65/4885RAB9A 379/4885BRAF 3603/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | NPC1 3136/4885RAB9A 1587/4885BRAF 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.